203 related articles for article (PubMed ID: 23979860)
1. Anti-JCV antibodies detection and JCV DNA levels in PBMC, serum and urine in a cohort of Spanish Multiple Sclerosis patients treated with natalizumab.
Dominguez-Mozo MI; Garcia-Montojo M; De Las Heras V; Garcia-Martinez A; Arias-Leal AM; Casanova I; Arroyo R; Alvarez-Lafuente R
J Neuroimmune Pharmacol; 2013 Dec; 8(5):1277-86. PubMed ID: 23979860
[TBL] [Abstract][Full Text] [Related]
2. Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort.
Trampe AK; Hemmelmann C; Stroet A; Haghikia A; Hellwig K; Wiendl H; Goelz S; Ziegler A; Gold R; Chan A
Neurology; 2012 May; 78(22):1736-42. PubMed ID: 22592369
[TBL] [Abstract][Full Text] [Related]
3. Urinary JCV-DNA testing during natalizumab treatment may increase accuracy of PML risk stratification.
Laroni A; Giacomazzi CG; Grimaldi L; Gallo P; Sormani MP; Bertolotto A; McDermott JL; Gandoglia I; Martini I; Vitello G; Rinaldi F; Barzon L; Militello V; Pizzorno M; Bandini F; Capello E; Palù G; Uccelli A; Mancardi GL; Varnier OE
J Neuroimmune Pharmacol; 2012 Sep; 7(3):665-72. PubMed ID: 22585413
[TBL] [Abstract][Full Text] [Related]
4. JC virus reactivation during prolonged natalizumab monotherapy for multiple sclerosis.
Chalkias S; Dang X; Bord E; Stein MC; Kinkel RP; Sloane JA; Donnelly M; Ionete C; Houtchens MK; Buckle GJ; Batson S; Koralnik IJ
Ann Neurol; 2014 Jun; 75(6):925-34. PubMed ID: 24687904
[TBL] [Abstract][Full Text] [Related]
5. JC virus in CD34+ and CD19+ cells in patients with multiple sclerosis treated with natalizumab.
Frohman EM; Monaco MC; Remington G; Ryschkewitsch C; Jensen PN; Johnson K; Perkins M; Liebner J; Greenberg B; Monson N; Frohman TC; Douek D; Major EO
JAMA Neurol; 2014 May; 71(5):596-602. PubMed ID: 24664166
[TBL] [Abstract][Full Text] [Related]
6. Absence of JC polyomavirus in stool samples of patients with multiple sclerosis despite high anti-JCV antibodies in serum.
Schweitzer F; Ladwig A; Opala S; Laurent S; Schroeter M; Goelz S; Fink GR; Wieland U; Silling S; Warnke C
Mult Scler Relat Disord; 2024 Jul; 87():105664. PubMed ID: 38735204
[TBL] [Abstract][Full Text] [Related]
7. A second-generation ELISA (STRATIFY JCV™ DxSelect™) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification.
Lee P; Plavina T; Castro A; Berman M; Jaiswal D; Rivas S; Schlain B; Subramanyam M
J Clin Virol; 2013 Jun; 57(2):141-6. PubMed ID: 23465394
[TBL] [Abstract][Full Text] [Related]
8. JCV detection in multiple sclerosis patients treated with natalizumab.
Sadiq SA; Puccio LM; Brydon EW
J Neurol; 2010 Jun; 257(6):954-8. PubMed ID: 20052484
[TBL] [Abstract][Full Text] [Related]
9. Study of the anti-JCV antibody levels in a Spanish multiple sclerosis cohort.
Dominguez-Mozo MI; Rus M; Santiago JL; Izquierdo G; Casanova I; Galan V; Garcia-Martinez MA; Arias-Leal AM; García-Montojo M; Pérez-Pérez S; Arroyo R; Alvarez-Lafuente R
Eur J Clin Invest; 2017 Feb; 47(2):158-166. PubMed ID: 28036121
[TBL] [Abstract][Full Text] [Related]
10. Assessment of JC virus DNA in blood and urine from natalizumab-treated patients.
Rudick RA; O'Connor PW; Polman CH; Goodman AD; Ray SS; Griffith NM; Jurgensen SA; Gorelik L; Forrestal F; Sandrock AW; Goelz SE
Ann Neurol; 2010 Sep; 68(3):304-10. PubMed ID: 20737514
[TBL] [Abstract][Full Text] [Related]
11. The effect of plasma exchange on serum anti-JC virus antibodies.
Subramanyam M; Plavina T; Khatri BO; Fox RJ; Goelz SE
Mult Scler; 2013 Jun; 19(7):912-9. PubMed ID: 23232602
[TBL] [Abstract][Full Text] [Related]
12. JC virus urinary excretion and seroprevalence in natalizumab-treated multiple sclerosis patients.
Delbue S; Elia F; Carloni C; Pecchenini V; Franciotta D; Gastaldi M; Colombo E; Signorini L; Carluccio S; Bellizzi A; Bergamaschi R; Ferrante P
J Neurovirol; 2015 Dec; 21(6):645-52. PubMed ID: 25052191
[TBL] [Abstract][Full Text] [Related]
13. Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy.
Warnke C; von Geldern G; Markwerth P; Dehmel T; Hoepner R; Gold R; Pawlita M; Kümpfel T; Mäurer M; Stangel M; Wegner F; Hohlfeld R; Straeten V; Limmroth V; Weber T; Hermsen D; Kleinschnitz C; Hartung HP; Wattjes MP; Svenningson A; Major E; Olsson T; Kieseier BC; Adams O
Ann Neurol; 2014 Dec; 76(6):792-801. PubMed ID: 24729444
[TBL] [Abstract][Full Text] [Related]
14. Nearly one-half of Brazilian patients with multiple sclerosis using natalizumab are DNA-JC virus positive.
Fragoso YD; Mendes MF; Arruda WO; Becker J; Brooks JB; Carvalho Mde J; Comini-Frota ER; Domingues RB; Ferreira ML; Finkelsztejn A; Gama PD; Gomes S; Gonçalves MV; Kaimen-Maciel DR; Morales Rde R; Muniz A; Ruocco HH; Salgado PR; Albuquerque LB; Gama RA; Georgeto S; Lopes J; Oliveira CL; Oliveira FT; Safanelli J; Saldanha PC; Satomi M
Arq Neuropsiquiatr; 2013 Oct; 71(10):780-2. PubMed ID: 24212514
[TBL] [Abstract][Full Text] [Related]
15. Changes to anti-JCV antibody levels in a Swedish national MS cohort.
Warnke C; Ramanujam R; Plavina T; Bergström T; Goelz S; Subramanyam M; Kockum I; Rahbar A; Kieseier BC; Holmén C; Olsson T; Hillert J; Fogdell-Hahn A
J Neurol Neurosurg Psychiatry; 2013 Nov; 84(11):1199-205. PubMed ID: 23463870
[TBL] [Abstract][Full Text] [Related]
16. Anti-JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy.
Plavina T; Subramanyam M; Bloomgren G; Richman S; Pace A; Lee S; Schlain B; Campagnolo D; Belachew S; Ticho B
Ann Neurol; 2014 Dec; 76(6):802-12. PubMed ID: 25273271
[TBL] [Abstract][Full Text] [Related]
17. Anti-JC virus seroprevalence in a Finnish MS cohort.
Kolasa M; Hagman S; Verkkoniemi-Ahola A; Airas L; Koivisto K; Elovaara I
Acta Neurol Scand; 2016 May; 133(5):391-7. PubMed ID: 26347001
[TBL] [Abstract][Full Text] [Related]
18. Anti-JCV antibody prevalence in a French cohort of MS patients under natalizumab therapy.
Outteryck O; Ongagna JC; Duhamel A; Zéphir H; Collongues N; Lacour A; Fleury MC; Berteloot AS; Blanc F; Giroux M; Vermersch P; de Sèze J
J Neurol; 2012 Nov; 259(11):2293-8. PubMed ID: 22527227
[TBL] [Abstract][Full Text] [Related]
19. Anti-JCV antibody serostatus and longitudinal evaluation in a Portuguese Multiple Sclerosis population.
Correia I; Jesus-Ribeiro J; Batista S; Martins AI; Nunes C; Macário MC; Cunha L; Sousa L
J Clin Neurosci; 2017 Nov; 45():257-260. PubMed ID: 28844615
[TBL] [Abstract][Full Text] [Related]
20. Monitoring the John Cunningham virus throughout natalizumab treatment in multiple sclerosis patients.
Domínguez-Mozo MI; García-Montojo M; Arias-Leal A; García-Martínez Á; Santiago JL; Casanova I; Galán V; Arroyo R; Fernández-Arquero M; Alvarez-Lafuente R
Eur J Neurol; 2016 Jan; 23(1):182-9. PubMed ID: 26498276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
